BREAKING
Herc Holdings Releases Q1 2026 Financial Results 1 minute ago Pentair Releases Q1 2026 Financial Results 4 minutes ago Kimberly-Clark Releases Q1 2026 Financial Results 5 minutes ago General Motors Releases Q1 2026 Financial Results 9 minutes ago Avery Dennison Releases Q1 2026 Financial Results 9 minutes ago Curbline Properties Releases Q1 2026 Financial Results 11 minutes ago PJT Partners Releases Q1 2026 Financial Results 13 minutes ago Zimmer Biomet Holdings Releases Q1 2026 Financial Results 16 minutes ago TransUnion Releases Q1 2026 Financial Results 21 minutes ago Centene Releases Q1 2026 Financial Results 22 minutes ago Herc Holdings Releases Q1 2026 Financial Results 1 minute ago Pentair Releases Q1 2026 Financial Results 4 minutes ago Kimberly-Clark Releases Q1 2026 Financial Results 5 minutes ago General Motors Releases Q1 2026 Financial Results 9 minutes ago Avery Dennison Releases Q1 2026 Financial Results 9 minutes ago Curbline Properties Releases Q1 2026 Financial Results 11 minutes ago PJT Partners Releases Q1 2026 Financial Results 13 minutes ago Zimmer Biomet Holdings Releases Q1 2026 Financial Results 16 minutes ago TransUnion Releases Q1 2026 Financial Results 21 minutes ago Centene Releases Q1 2026 Financial Results 22 minutes ago
ADVERTISEMENT
JNJ

Johnson & Johnson

$JNJ NYSE May 27, 2026 DMH FY 2026

Investor Toolbox

Listen to Call

Watch or listen to the earnings call recording.

Open Webcast

Read Transcript

Transcript not yet available.

View Infographic

Visual summary of key financial data.

View Infographic

Earnings History

View past quarters and earnings trends.

View History

JNJ Coverage

Event Johnson & Johnson (JNJ) FDA grants Priority Review for IMAAVY® (nipocalimab-aahu) as the potential first approved treatment for people living with warm autoimmune hemolytic anemia (wAIHA) Apr 27, 2026 Event Johnson & Johnson (JNJ) Sec Form 10Q Apr 23, 2026 Event Johnson & Johnson (JNJ) IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG) Apr 22, 2026 Transcript Johnson & Johnson (JNJ) Q1 2026 Earnings Call Transcript Apr 14, 2026 News Johnson & Johnson (JNJ) Earnings: 1Q26 Key Numbers Apr 14, 2026 News Johnson & Johnson likely to report mixed results for Q1 FY26 Apr 7, 2026 Transcript Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript Jan 26, 2026 Transcript Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript Jan 22, 2026